DexCom, Inc. (DXCM) is a Medical - Devices company in the Healthcare sector, currently trading at $62.95. It has a SharesGrow Score of 82/100, indicating a strong investment profile with 7 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of DXCM = $98.26 (+56.1% from the current price, the stock appears undervalued). Analyst consensus target is DXCM = $86 (+36.3% upside).
Valuation: DXCM trades at a trailing Price-to-Earnings (P/E) of 30.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.48.
Financials: revenue is $4.7B, +17.1%/yr average growth. Net income is $836M, growing at +36.8%/yr. Net profit margin is 17.9% (healthy). Gross margin is 60.1% (-4.6 pp trend).
Balance sheet: total debt is $1.4B against $2.7B equity (Debt-to-Equity (D/E) ratio 0.51, moderate). Current ratio is 1.88 (strong liquidity). Debt-to-assets is 21.9%. Total assets: $6.3B.
Analyst outlook: 42 / 52 analysts rate DXCM as buy (81%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 69/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 71/100 (Pass), Future 94/100 (Pass), Income 70/100 (Pass).
